Skip to main content
Premium Trial:

Request an Annual Quote

Now for HIV

Moderna is poised to begin a trial of an mRNA-based vaccine for HIV, Gizmodo reports. It adds that new trial registration data indicates the company is starting a small phase I clinical trial of its HIV vaccine, dubbed mRNA-1644, in 56 people.

Popular Science notes that HIV has been a particularly difficult virus for vaccine developers because of how quickly it integrates into the human genome. To prevent infection, it says that a high level of antibodies must be present at exposure. Gizmodo writes that Moderna is hoping that its mRNA-based approach in combination with a new way of eliciting antibodies will be effective.

Following successes with mRNA-based vaccines for SARS-CoV-2, Moderna, BioNTech, and others are moving ahead with work on vaccines for other diseases, including the flumalaria, tuberculosis, and cancer.

"We've had an incredible year using messenger RNA to fight a pandemic," Stephen Hoge, president of Moderna, told CBS Sunday Morning in June. "But we think we're just starting in the infectious disease space. And so, there's a large number of other vaccines we're bringing forward."

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.